Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
VitaNova Life Sciences Corp (VNOV)
Price$2.38Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.7M | $570,694 | $38,000 | $120,000 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $910,589 | $1.6M | $377,711 | $38,000 | — | — | — | $0 | $0 | $0 |
| Gross margin | 30.10% | 59.19% | 66.18% | 100.00% | — | — | — | — | — | — |
| Operating expenses | $906,988 | $367,396 | $172,082 | $62,227 | $133,367 | $52,094 | $72,334 | $71,811 | $48,649 | $7,175 |
| Operating income | $3,601 | $1.2M | $205,629 | −$24,227 | −$13,367 | −$52,094 | −$72,334 | −$71,811 | −$48,649 | — |
| Operating margin | 0.12% | 45.39% | 36.03% | −63.76% | −11.14% | — | — | — | — | — |
| EBITDA | $6,581 | $1.2M | $205,734 | −$24,227 | — | — | — | −$71,811 | −$48,649 | — |
| EBITDA margin | 0.22% | 45.41% | 36.05% | −63.76% | — | — | — | — | — | — |
| Net income | −$37,304 | $850,746 | $140,865 | −$24,227 | $139,682 | −$52,094 | −$72,334 | −$106,167 | −$1,595 | −$7,175 |
| Net profit margin | −1.23% | 31.96% | 24.68% | −63.76% | 116.40% | — | — | — | — | — |
| Basic EPSper basic share | -$0.00 | $0.10 | $0.03 | $0.00 | $0.06 | -$0.03 | $0.00 | $0.00 | $0.00 | — |
| Diluted EPSper diluted share | — | $0.09 | $0.03 | $0.00 | $0.06 | -$0.03 | $0.00 | $0.00 | $0.00 | — |
Owners
Reported shareholders